A new paper examined the retinal data from Parkinson disease patients in attempt to identify disease markers.
The problem with potential changes to the biosimilar regulatory framework
Biosimilars are no longer a new and untested class of medicines. Today, they provide critical treatment options across multiple therapeutic areas. Since the Biologics Price